Research
Hormonal
GLP-1 receptor agonists do not exacerbate psychotic symptoms in schizophrenia and provide metabolic benefits, but have not demonstrated consistent effects on core psychiatric symptomatology.
For people with schizophrenia, GLP-1 medications are safe and help with weight gain caused by antipsychotics, but they do not treat the psychosis itself. Do not expect them to improve hallucinations or cognitive function. They are a tool for metabolic health, not psychiatric symptom management in this population.
ModerateQualifiesLOW confidence
In schizophrenia, GLP-1RAs provide clear metabolic benefits but have not demonstrated consistent effects on psychiatric symptomatology... Meta-analyses have found no evidence that GLP-1RAs exacerbate psychotic symptoms.
Why this rating
Based on limited human studies and preclinical models; human data is inconclusive.
Source
Psychiatric effects of <scp>GLP</scp> ‐1 receptor agonists: A systematic review of emerging evidence
Brianna Sa et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.70198
Meta-analysis · 38 studiesCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists significantly reduce binge eating behaviors and alcohol consumption, offering therapeutic potential for substance use disorders and eating disorders independent of weight loss.Good
- GLP-1 receptor agonists (GLP-1RAs) provide modest antidepressant effects and reduce binge eating behaviors, but their impact on suicidality remains uncertain and potentially elevated in high-risk subgroups.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →